Literature DB >> 19891905

A modern approach to the treatment of mitochondrial disease.

Sumit Parikh1, Russell Saneto, Marni J Falk, Irina Anselm, Bruce H Cohen, Richard Haas, The Mitochondrial Medicine Society.   

Abstract

The treatment of mitochondrial disease varies considerably. Most experts use a combination of vitamins, optimize patients' nutrition and general health, and prevent worsening of symptoms during times of illness and physiologic stress. We agree with this approach, and we agree that therapies using vitamins and cofactors have value, though there is debate about the choice of these agents and the doses prescribed. Despite the paucity of high-quality scientific evidence, these therapies are relatively harmless, may alleviate select clinical symptoms, and theoretically may offer a means of staving off disease progression. Like many other mitochondrial medicine physicians, we have observed significant (and at times life-altering) clinical responses to such pharmacologic interventions. However, it is not yet proven that these therapies truly alter the course of the disease, and some experts may choose not to use these medications at all. At present, the evidence of their effectiveness does not rise to the level required for universal use. Based on our clinical experience and judgment, however, we agree that a therapeutic trial of coenzyme Q10, along with other antioxidants, should be attempted. Although individual specialists differ as to the exact drug cocktail, a common approach involves combinations of antioxidants that may have a synergistic effect. Because almost all relevant therapies are classified as medical foods or over-the-counter supplements, most physicians also attempt to balance the apparent clinical benefit of mitochondrial cocktails with the cost burden that these supplements pose for the family.

Entities:  

Year:  2009        PMID: 19891905      PMCID: PMC3561461          DOI: 10.1007/s11940-009-0046-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  65 in total

1.  Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies.

Authors:  A Borchert; E Wilichowski; F Hanefeld
Journal:  Muscle Nerve       Date:  1999-09       Impact factor: 3.217

2.  Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease.

Authors:  M A Tarnopolsky; G Parise
Journal:  Muscle Nerve       Date:  1999-09       Impact factor: 3.217

3.  Cost-effectiveness of implantable cardioverter-defibrillators.

Authors:  Gillian D Sanders; Mark A Hlatky; Douglas K Owens
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

4.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.

Authors:  Marcus A Bain; Randall Faull; Gianfranco Fornasini; Robert W Milne; Allan M Evans
Journal:  Nephrol Dial Transplant       Date:  2006-01-09       Impact factor: 5.992

Review 5.  Toxicology of oral antidiabetic medications.

Authors:  Henry A Spiller; Tama S Sawyer
Journal:  Am J Health Syst Pharm       Date:  2006-05-15       Impact factor: 2.637

6.  Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome.

Authors:  C T Spencer; B J Byrne; M H Gewitz; S B Wechsler; A C Kao; E P Gerstenfeld; A D Merliss; M P Carboni; R M Bryant
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

Review 7.  Mitochondrial DNA shifting in older adults following resistance exercise training.

Authors:  M A Tarnopolsky
Journal:  Appl Physiol Nutr Metab       Date:  2009-06       Impact factor: 2.665

8.  Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.

Authors:  Clifford W Shults; M Flint Beal; David Song; Deborah Fontaine
Journal:  Exp Neurol       Date:  2004-08       Impact factor: 5.330

9.  Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency.

Authors:  David P Dimmock; J Kay Dunn; Annette Feigenbaum; Anthony Rupar; Rita Horvath; Peter Freisinger; Bénédicte Mousson de Camaret; Lee-Jun Wong; Fernando Scaglia
Journal:  Liver Transpl       Date:  2008-10       Impact factor: 5.799

10.  The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children.

Authors:  J M Freeman; E P Vining; D J Pillas; P L Pyzik; J C Casey; L M Kelly
Journal:  Pediatrics       Date:  1998-12       Impact factor: 7.124

View more
  107 in total

1.  [Characteristics of anesthesia in patients with MELAS syndrome: Case report of anesthesia in video-assisted thoracoscopy].

Authors:  A Haas; F Wappler
Journal:  Anaesthesist       Date:  2015-08-28       Impact factor: 1.041

Review 2.  Schwann cell mitochondria as key regulators in the development and maintenance of peripheral nerve axons.

Authors:  Daisuke Ino; Masamitsu Iino
Journal:  Cell Mol Life Sci       Date:  2016-09-16       Impact factor: 9.261

3.  Inhibiting cytosolic translation and autophagy improves health in mitochondrial disease.

Authors:  Min Peng; Julian Ostrovsky; Young Joon Kwon; Erzsebet Polyak; Joseph Licata; Mai Tsukikawa; Eric Marty; Jeffrey Thomas; Carolyn A Felix; Rui Xiao; Zhe Zhang; David L Gasser; Yair Argon; Marni J Falk
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

4.  Which approach is better: bilateral versus unilateral thalamic deep brain stimulation in patients with fragile X-associated tremor ataxia syndrome.

Authors:  R Mehanna; I Itin
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

5.  Maternal Multiple Micronutrient Supplementation Stabilizes Mitochondrial DNA Copy Number in Pregnant Women in Lombok, Indonesia.

Authors:  Lidwina Priliani; Elizabeth L Prado; Restuadi Restuadi; Diana E Waturangi; Anuraj H Shankar; Safarina G Malik
Journal:  J Nutr       Date:  2019-08-01       Impact factor: 4.798

6.  Problems of adults with a mitochondrial disease - the patients' perspective: focus on loss.

Authors:  Greet Noorda; Theo van Achterberg; Truus van der Hooft; Jan Smeitink; Lisette Schoonhoven; Baziel van Engelen
Journal:  JIMD Rep       Date:  2012-02-24

7.  Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish.

Authors:  James Byrnes; Rebecca Ganetzky; Richard Lightfoot; Michael Tzeng; Eiko Nakamaru-Ogiso; Christoph Seiler; Marni J Falk
Journal:  Neurochem Int       Date:  2017-07-18       Impact factor: 3.921

8.  RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury.

Authors:  Ilias I Siempos; Kevin C Ma; Mitsuru Imamura; Rebecca M Baron; Laura E Fredenburgh; Jin-Won Huh; Jong-Seok Moon; Eli J Finkelsztein; Daniel S Jones; Michael Torres Lizardi; Edward J Schenck; Stefan W Ryter; Kiichi Nakahira; Augustine Mk Choi
Journal:  JCI Insight       Date:  2018-05-03

Review 9.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

Review 10.  Anesthetic considerations in patients with mitochondrial defects.

Authors:  Julie Niezgoda; Phil G Morgan
Journal:  Paediatr Anaesth       Date:  2013-03-28       Impact factor: 2.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.